132 related articles for article (PubMed ID: 36706701)
21. TH1/TH2 Cytokine profile in relapsing-remitting multiple sclerosis patients treated with Glatiramer acetate or Natalizumab.
Oreja-Guevara C; Ramos-Cejudo J; Aroeira LS; Chamorro B; Diez-Tejedor E
BMC Neurol; 2012 Sep; 12():95. PubMed ID: 22989378
[TBL] [Abstract][Full Text] [Related]
22. Genetic regulation of IL-8 influences disease presentation of multiple sclerosis.
Dolcetti E; Bruno A; Azzolini F; Gilio L; Pavone L; Iezzi E; Galifi G; Gambardella S; Ferese R; Buttari F; De Vito F; Colantuono P; Furlan R; Finardi A; Musella A; Mandolesi G; Centonze D; Stampanoni Bassi M
Mult Scler; 2023 Apr; 29(4-5):512-520. PubMed ID: 36803228
[TBL] [Abstract][Full Text] [Related]
23. Increased interleukin-27 cytokine expression in the central nervous system of multiple sclerosis patients.
Lalive PH; Kreutzfeldt M; Devergne O; Metz I; Bruck W; Merkler D; Pot C
J Neuroinflammation; 2017 Jul; 14(1):144. PubMed ID: 28738904
[TBL] [Abstract][Full Text] [Related]
24. Changes in Cerebrospinal Fluid Balance of TNF and TNF Receptors in Naïve Multiple Sclerosis Patients: Early Involvement in Compartmentalised Intrathecal Inflammation.
Magliozzi R; Pezzini F; Pucci M; Rossi S; Facchiano F; Marastoni D; Montagnana M; Lippi G; Reynolds R; Calabrese M
Cells; 2021 Jul; 10(7):. PubMed ID: 34359880
[TBL] [Abstract][Full Text] [Related]
25. Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
Tawfik TZ; Gad AH; Mehaney DA; El Nahrery E; Shehata HS; Hashem H; Ghaffar NFA; Shalaby N
J Neurol Sci; 2016 Oct; 369():36-38. PubMed ID: 27653861
[TBL] [Abstract][Full Text] [Related]
26. Plasma Interleukin-33 level in relapsing-remitting multiple sclerosis. Is it negatively correlated with central nervous system lesions in patients with mild disability?
Mado H; Adamczyk-Sowa M; Bartman W; Wierzbicki K; Tadeusiak B; Sowa P
Clin Neurol Neurosurg; 2021 Jul; 206():106700. PubMed ID: 34030079
[TBL] [Abstract][Full Text] [Related]
27. CSF Levels of CXCL12 and Osteopontin as Early Markers of Primary Progressive Multiple Sclerosis.
Marastoni D; Magliozzi R; Bolzan A; Pisani AI; Rossi S; Crescenzo F; Montemezzi S; Pizzini FB; Calabrese M
Neurol Neuroimmunol Neuroinflamm; 2021 Nov; 8(6):. PubMed ID: 34588298
[TBL] [Abstract][Full Text] [Related]
28. Effect of high dose vitamin D intake on interleukin-17 levels in multiple sclerosis: a randomized, double-blind, placebo-controlled clinical trial.
Toghianifar N; Ashtari F; Zarkesh-Esfahani SH; Mansourian M
J Neuroimmunol; 2015 Aug; 285():125-8. PubMed ID: 26198928
[TBL] [Abstract][Full Text] [Related]
29. Immune Parameters That Distinguish Multiple Sclerosis Patients from Patients with Other Neurological Disorders at Presentation.
Mouzaki A; Rodi M; Dimisianos N; Emmanuil A; Kalavrizioti D; Lagoudaki R; Grigoriadis NC; Papathanasopoulos P
PLoS One; 2015; 10(8):e0135434. PubMed ID: 26317430
[TBL] [Abstract][Full Text] [Related]
30. A clinical and laboratory study evaluating the profile of cytokine levels in relapsing remitting and secondary progressive multiple sclerosis.
Pasquali L; Lucchesi C; Pecori C; Metelli MR; Pellegrini S; Iudice A; Bonuccelli U
J Neuroimmunol; 2015 Jan; 278():53-9. PubMed ID: 25595252
[TBL] [Abstract][Full Text] [Related]
31. Biomarkers of inflammation and axonal degeneration/damage in patients with newly diagnosed multiple sclerosis: contributions of the soluble CD163 CSF/serum ratio to a biomarker panel.
Stilund M; Gjelstrup MC; Petersen T; Møller HJ; Rasmussen PV; Christensen T
PLoS One; 2015; 10(4):e0119681. PubMed ID: 25860354
[TBL] [Abstract][Full Text] [Related]
32. Lipoprotein profiling in early multiple sclerosis patients: effect of chronic inflammation?
Rádiková Ž; Penesová A; Vlček M; Havranová A; Siváková M; Šiarnik P; Žitňanová I; Imrich R; Turčáni P; Kollár B
Lipids Health Dis; 2020 Mar; 19(1):49. PubMed ID: 32178676
[TBL] [Abstract][Full Text] [Related]
33. T helper 9 cells induced by plasmacytoid dendritic cells regulate interleukin-17 in multiple sclerosis.
Ruocco G; Rossi S; Motta C; Macchiarulo G; Barbieri F; De Bardi M; Borsellino G; Finardi A; Grasso MG; Ruggieri S; Gasperini C; Furlan R; Centonze D; Battistini L; Volpe E
Clin Sci (Lond); 2015 Aug; 129(4):291-303. PubMed ID: 25700150
[TBL] [Abstract][Full Text] [Related]
34. Interleukin-1 receptor antagonist: An exploratory plasma biomarker that correlates with disability and provides pathophysiological insights in relapsing-remitting multiple sclerosis.
Blandford SN; Galloway DA; Williams JB; Arsenault S; Brown J; MacLean G; Moore GRW; Barron J; Ploughman M; Clift F; Stefanelli M; Moore CS
Mult Scler Relat Disord; 2021 Jul; 52():103006. PubMed ID: 34004435
[TBL] [Abstract][Full Text] [Related]
35. Elevated cerebrospinal fluid interleukin-17A and interferon-γ levels in early asymptomatic neurosyphilis.
Pastuszczak M; Jakiela B; Wielowieyska-Szybinska D; Jaworek AK; Zeman J; Wojas-Pelc A
Sex Transm Dis; 2013 Oct; 40(10):808-12. PubMed ID: 24275734
[TBL] [Abstract][Full Text] [Related]
36. Evidence of altered Th17 pathway signatures in the cerebrospinal fluid of patients with Guillain Barré Syndrome.
Debnath M; Nagappa M; Dutta D; Talukdar PM; Subbanna M; Shivakumar V; Wahatule R; Sinha S; Bindu PS; Periyavan S; Umamaheswara Rao GS; Kumar MA; Taly AB
J Clin Neurosci; 2020 May; 75():176-180. PubMed ID: 32217048
[TBL] [Abstract][Full Text] [Related]
37. CSF levels of soluble HLA-G and Fas molecules are inversely associated to MRI evidence of disease activity in patients with relapsing-remitting multiple sclerosis.
Fainardi E; Rizzo R; Melchiorri L; Stignani M; Castellazzi M; Tamborino C; Paolino E; Tola MR; Granieri E; Baricordi OR
Mult Scler; 2008 May; 14(4):446-54. PubMed ID: 18208868
[TBL] [Abstract][Full Text] [Related]
38. Clinical and laboratory study of pro-inflammatory and antiinflammatory cytokines in women with multiple sclerosis.
Trenova AG; Manova MG; Kostadinova II; Murdjeva MA; Hristova DR; Vasileva TV; Zahariev ZI
Folia Med (Plovdiv); 2011; 53(2):29-35. PubMed ID: 21797104
[TBL] [Abstract][Full Text] [Related]
39. Characterization of IL-17AA and IL-17FF in rheumatoid arthritis and multiple sclerosis.
Schofield C; Fischer SK; Townsend MJ; Mosesova S; Peng K; Setiadi AF; Song A; Baruch A
Bioanalysis; 2016 Nov; 8(22):2317-2327. PubMed ID: 27620302
[TBL] [Abstract][Full Text] [Related]
40. Profiling of Canonical and Non-Traditional Cytokine Levels in Interferon-β-Treated Relapsing-Remitting-Multiple Sclerosis Patients.
D'Angelo C; Reale M; Costantini E; Di Nicola M; Porfilio I; de Andrés C; Fernández-Paredes L; Sánchez-Ramón S; Pasquali L
Front Immunol; 2018; 9():1240. PubMed ID: 29915590
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
